Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful hard but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the last several shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set away the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a highly promotional image in the Uptick Newswire employment interview which I came away with a bad opinion of the business.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, however, the disappointment has not been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the technology and also linked intellectual property coming from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) and the first new drug program approval ($5 million), as well as royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with multiple therapies and numerous indications, it’s this individual treatments in addition to a “broad pipeline of indications” as it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its site (below) shows an active company with diverse interests albeit centered on leronlimab, several disease types, multiple publications in addition to multiple delivering presentations.

Can all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the really beginning of the interest of mine in this business. Judging by the multiples of a huge number of various comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this particular question.

CytoDyn is a classic battleground, or perhaps some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *